Head-To-Head Survey: Kronos Bio (NASDAQ:KRON) versus Chemomab Therapeutics (NASDAQ:CMMB)

Chemomab Therapeutics (NASDAQ:CMMBGet Free Report) and Kronos Bio (NASDAQ:KRONGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Institutional & Insider Ownership

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 64.1% of Kronos Bio shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 24.4% of Kronos Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Chemomab Therapeutics and Kronos Bio”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chemomab Therapeutics N/A N/A -$24.22 million ($1.14) -1.31
Kronos Bio $6.29 million 7.91 -$112.67 million ($1.74) -0.47

Chemomab Therapeutics has higher earnings, but lower revenue than Kronos Bio. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Chemomab Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Chemomab Therapeutics and Kronos Bio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemomab Therapeutics 0 0 3 1 3.25
Kronos Bio 0 0 2 0 3.00

Chemomab Therapeutics presently has a consensus target price of $5.67, indicating a potential upside of 280.31%. Kronos Bio has a consensus target price of $4.13, indicating a potential upside of 400.00%. Given Kronos Bio’s higher probable upside, analysts clearly believe Kronos Bio is more favorable than Chemomab Therapeutics.

Profitability

This table compares Chemomab Therapeutics and Kronos Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chemomab Therapeutics N/A -102.80% -76.79%
Kronos Bio -1,222.83% -68.82% -51.52%

Summary

Kronos Bio beats Chemomab Therapeutics on 7 of the 13 factors compared between the two stocks.

About Chemomab Therapeutics

(Get Free Report)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

About Kronos Bio

(Get Free Report)

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.